Abstract

Objective To estimate the high risk group for cardiovascular disease in a well defined Norwegian population according to European guidelines and the systematic coronary risk evaluation system.

Design Modelling study.

Setting Nord-Trøndelag health study 1995-7 (HUNT 2), Norway.

Participants 5548 participants of the Nord-Trøndelag health study 1995-7, aged 40, 50, 55, 60, and 65.

Main outcome measures Distribution of risk categories for cardiovascular disease, with emphasis on the high risk group.

Main results At age 40, 22.5% (95% confidence interval 19.3% to 25.7%) of women and 85.9% (83.2% to 88.6%) of men were at high risk of cardiovascular disease. Corresponding numbers at age 50 were 39.5% (35.9% to 43.1%) and 88.7% (86.3% to 91.0%) and at age 65 were 84.0% (80.6% to 87.4%) and 91.6% (88.6% to 94.1%). At age 40, one out of 10 women and no men would be classified at low risk for cardiovascular disease.

Conclusion Implementation of the 2003 European guidelines on prevention of cardiovascular disease in clinical practice would classify most adult Norwegians at high risk for fatal cardiovascular disease.

Introduction

Mortality from cardiovascular disease has declined considerably in most European countries since the early 1970s.1 Interventions to modify risk factors have long been shown to reduce mortality and morbidity from cardiovascular disease, in both people with previously unrecognised disease and people with established disease.2 Intervention in people at high risk is an accepted method for disease prevention. Since the first US Framingham model for predicting heart disease risk was published in 1991, it has become even more widely recommended that doctors in primary care carry out risk assessment by combining several risk factors for cardiovascular disease using algorithms. Until recently most risk equations have been derived from the Framingham study, but these calculations tended to overestimate risk in the European context. A new European risk scoring system for cardiovascular disease, based on the first phase of the systematic coronary risk evaluation (SCORE) project, was presented in 2003.3 The system is based on a pooled dataset of cohort studies from 12 European countries, among these Norway, and offers a format for estimating fatal cardiovascular disease risk that is suitable for clinical practice.3 The system is embedded in the current version of the European guidelines on prevention of cardiovascular disease, issued by the Third Joint Task Force of European and other Societies on Cardiovascular Disease Prevention in Clinical Practice in 2003.4 The authoring body consists of eight European and international medical societies and experts. The guidelines aim to present all relevant evidence to facilitate clinical decision making in the primary and secondary prevention of cardiovascular disease, which can be adapted to different political, economic, social, and medical circumstances.5

The legal status of clinical guidelines for the prevention of disease is not fully established,6 but authoritative recommendations contribute to expert and opinion leaders’ definition of what constitutes good medical practice. Several studies have, however, shown clinicians’ limited adherence to medical guidelines for asymptomatic conditions.7-9 This is the case even in high risk situations, such as patients with angina pectoris or diabetes mellitus.8 This phenomenon, termed “clinical inertia,” has been partly attributed to too much work, too little time, and “soft reasons to avoid intensification of therapy.”10 Population based data on risk factors for cardiovascular disease are available for many European regions.11 The 2003 European guidelines, however, provide no estimates of the aggregated workload associated with implementation of the recommendations. We recently showed that implementation would result in three out of four Norwegians aged 20 or older being classed as in need of counselling because of high cholesterol or blood pressure levels.12

We estimated the high risk group in the Norwegian population participating in the Nord-Trøndelag health study 1995-7 (HUNT 2),12 according to the 2003 European guidelines on prevention of cardiovascular disease.

Materials and methods

The 2003 European guidelines tackle the prevention of atherosclerotic disease in general (coronary heart disease, peripheral artery disease, and cerebrovascular atherosclerotic disease). Risk is defined in terms of the absolute probability of developing a fatal cardiovascular event within 10 years, and the threshold for high risk is defined as ≥ 5%.6 The guidelines specify a list of biomedical conditions that classify people at high risk (see box). These people require maximal clinical attention, with no further estimation of risk.6 In remaining asymptomatic, apparently healthy people, risk estimation and counselling should be guided by the total risk level, as estimated from a chart produced by the systematic coronary risk evaluation project.
The Nord-Trøndelag health study 1995-7

Our population data were derived from the Nord-Trøndelag health study 1995-7, a large Norwegian population study that was designed to investigate the importance of biomedical risk factors. Its design and methods are described elsewhere.12 Data were obtained from 66 140 participants. The study population has been considered fairly representative of the Norwegian population for demography, socioeconomic factors, morbidity, and mortality.13

To apply the guidelines’ recommendations as precisely as possible, we included in the present analysis only people of the ages shown in the chart. The analysis is based on participants from the Nord-Trøndelag health study aged 40, 50, 55, 60, and 65 years, totalling 5548 people (2841 women, 2707 men). These participants answered two questionnaires; one sent by post in 60 years, totalling 5548 people (2841 women, 2707 men). These ages shown in the chart. The analysis is based on participants who fulfill criteria 1 or 2, or both are defined as at high risk.

The chart comprises a table of the parameters sex, smoking status, systolic blood pressure, total cholesterol (or ratio of total cholesterol to high density lipoprotein), and age (40, 50, 55, 60, and 65 years). Risk is estimated by rounding a person’s age to the nearest multiple of 20 mm Hg.3 The guidelines specifically recommend extrapolation of the risk estimate to 60 years when counselling people in the younger age groups. We calculated risk distribution both with and without extrapolation to evaluate its effect on the high risk group.

The chart is designed in two versions, for use in high or low risk populations. As the guidelines state that Norway is a high risk region, we analysed data using the high risk chart.

The guidelines encourage people with increased risk for cardiovascular disease to change their lifestyle.4 To facilitate communication of risk, a person’s combined risk estimate is visualised by “traffic light” colours. High risk is illustrated by increasingly dark shades of red. Intermediate risk (2%-4% risk of a fatal event within 10 years) is illustrated by yellow-orange, and low risk (≤ 1%) by green.

The Nord-Trøndelag health study population for demography, socioeconomic factors, morbidity, and mortality.15

To apply the guidelines’ recommendations as precisely as possible, we included in the present analysis only people of the ages shown in the chart. The analysis is based on participants from the Nord-Trøndelag health study aged 40, 50, 55, 60, and 65 years, totalling 5548 people (2841 women, 2707 men). These participants answered two questionnaires; one sent by post before screening and the other presented at screening. A range of health topics was covered.16 Of relevance to our study were questions about cardiovascular disease, diabetes mellitus, and smoking habits. For our analysis we define smoking as daily consumption of cigarettes, cigars, or a pipe.

In the Nord-Trøndelag health study, blood pressure was measured in seated participants by specially trained staff using a Dinamap 845XT based on oscillometry.17 In our analysis we record blood pressure as the mean values of the second and third of three measurements carried out consecutively at the same visit. Blood sampling was carried out whenever the participants attended—that is, in the non-fasting state. Fresh serum was analysed on a Hitachi 911 autoanlyser. Total cholesterol and high density lipoprotein cholesterol were measured by an enzymatic colorimetric cholesterol esterase method.18 Height was measured to the nearest 1.0 cm and weight to the nearest 0.5 kg. Body mass index was calculated.

Projection of the guidelines to the study population

We established the proportion of participants at high risk of cardiovascular disease in a stepwise manner, in accordance with the guidelines. We calculated the age and sex specific proportions that should be assigned to the high risk category on the basis of criteria 1 and 2b-c of the priority list (see box). We used the chart to estimate risk in the remaining participants. As the chart does not give exact cut-off points for systolic blood pressure and total cholesterol, we applied the following limits: systolic blood pressure (mm Hg) ≤ 119, 120-139, 140-159, and 160-179; total cholesterol (mmol/l) ≤ 3.9, 4.0-4.9, 5.0-5.9, 6.0-6.9, and 7.0-7.9.

Overall, 283 women (10% of the total) and 186 men (6.9%) were unclassifiable according to the chart owing to missing data, mostly on smoking habits. We included all participants in the denominator when we determined the distribution of risk categories.

We adapted the priority list on the basis of the data from the Nord-Trøndelag health study. Under criterion 1 we included only participants with a history of myocardial infarction or stroke. We did not calculate low density lipoprotein, as application of the Friedewald formula is unreliable in non-fasting people. We included participants who reported receiving treatment for hypertension and all people with diabetes mellitus in the high risk category.

We display graphically the risk distribution for cardiovascular disease among the Nord-Trøndelag health study population in two versions; one based on extrapolation to age 60 as recommended in the guidelines, the other based on the participants’ age. In doing so we applied the colour system, without differentiating between shades of the same colour. Shaded red indicates people who are defined as at high risk on the basis of criteria 1 and 2b-c. Unshaded red indicates high risk according to the chart (criterion 2a). We used SPSS version 12.0 to analyse frequencies.

Results

Table 1 gives an overview of participants from the Nord-Trøndelag health study included in the present analysis. The participation rate varied from 70% to 89%. Table 2 shows the proportion of people categorised as at high risk on the basis of noticeably raised levels of single risk factors (see box) and the distribution of the combined risk categories, according to the chart of the systematic coronary risk evaluation project.

If all recommendations including extrapolation of risk to 60 years are applied, 22.5% (95% confidence interval 19.3% to 25.7%) of women and 85.9% (83.2% to 88.6%) of men aged 40 are classified as at high risk for fatal cardiovascular disease (fig 1 and table 2). Only 8.5% (6.5% to 10.9%) of women and no men aged 40 are classified at low risk. By age 50, the high risk group includes 39.5% (35.9% to 43.1%) of women and 88.7% (86.3% to 91.0%) of men and by age 65, 84.0% (80.6% to 87.4%) of women and 91.6% (88.6% to 94.1%) of men.
Mostly explained by missing data on smoking habits.

Extrapolation to 60 years for ages 40, 50, and 55 (denominator is number of individuals in each cohort).

*One or more of following criteria present: myocardial infarction, stroke, antihypertensive treatment, diabetes, cholesterol ≥2.6 mmol/l, systolic blood pressure ≥180 mm Hg, diastolic blood pressure ≥110 mm Hg.

Figure 2 shows the distribution of risk categories without extrapolation to age 60. Extrapolation explains 86.0% of the high risk group after evaluation using the chart among women aged 55. The values for men are 64.4% at age 50 and 18.7% at age 55.

Discussion

Implementation of the 2003 European guidelines on prevention of cardiovascular disease in a well defined Norwegian population would class four out of 10 women and nine out of 10 men aged

<table>
<thead>
<tr>
<th>Variable</th>
<th>40 years</th>
<th>50 years</th>
<th>55 years</th>
<th>60 years</th>
<th>65 years</th>
</tr>
</thead>
<tbody>
<tr>
<td>No of participants (participation rate)</td>
<td>Women</td>
<td>657 (80.8)</td>
<td>624 (86.6)</td>
<td>709 (84.1)</td>
<td>698 (76.0)</td>
</tr>
<tr>
<td>Men</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mean (SD) systolic blood pressure</td>
<td>Women</td>
<td>124.0 (14.5)</td>
<td>133.0 (13.1)</td>
<td>133.1 (19.1)</td>
<td>137.5 (16.9)</td>
</tr>
<tr>
<td>Men</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mean (SD) diastolic blood pressure</td>
<td>Women</td>
<td>76.1 (9.8)</td>
<td>80.8 (9.8)</td>
<td>80.8 (11.2)</td>
<td>85.4 (10.9)</td>
</tr>
<tr>
<td>Men</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mean (SD) total cholesterol concentration</td>
<td>Women</td>
<td>5.4 (1.0)</td>
<td>5.7 (1.1)</td>
<td>6.1 (1.1)</td>
<td>6.1 (1.1)</td>
</tr>
<tr>
<td>Men</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mean (SD) body mass index</td>
<td>Women</td>
<td>25.4 (4.1)</td>
<td>26.3 (3.4)</td>
<td>26.5 (4.4)</td>
<td>27.0 (3.4)</td>
</tr>
<tr>
<td>Men</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Table 2</td>
<td>Participation rates, means, and prevalence of relevant risk factors among participants in Nord-Trøndelag health study 1995-7 (HUNT 2), Norway. Values are percentages (numbers) unless stated otherwise</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Variable</th>
<th>40 years</th>
<th>50 years</th>
<th>55 years</th>
<th>60 years</th>
<th>65 years</th>
</tr>
</thead>
<tbody>
<tr>
<td>Priority list:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Established myocardial infarction or stroke</td>
<td>Women</td>
<td>0.3 (2/657)</td>
<td>0.3 (2/624)</td>
<td>1.4 (10/708)</td>
<td>4.3 (30/698)</td>
</tr>
<tr>
<td>Men</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Systolic blood pressure ≥180 mm Hg or diastolic blood pressure ≥110 mm Hg</td>
<td>Women</td>
<td>0.5 (3/657)</td>
<td>0.5 (3/624)</td>
<td>2.4 (17/709)</td>
<td>2.1 (15/698)</td>
</tr>
<tr>
<td>Men</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cholesterol ≥2.6 mmol/l</td>
<td>Women</td>
<td>1.1 (7/654)</td>
<td>3.5 (22/622)</td>
<td>6.3 (45/699)</td>
<td>5.5 (38/696)</td>
</tr>
<tr>
<td>Men</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Diabetes</td>
<td>Women</td>
<td>0.3 (2/657)</td>
<td>1.3 (8/616)</td>
<td>2.3 (16/678)</td>
<td>1.6 (11/696)</td>
</tr>
<tr>
<td>Men</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Receiving treatment for hypertension</td>
<td>Women</td>
<td>1.8 (12/655)</td>
<td>1.8 (11/621)</td>
<td>8.1 (57/659)</td>
<td>9.3 (85/696)</td>
</tr>
<tr>
<td>Men</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sum high risk</td>
<td>Women</td>
<td>3.8 (25/657)</td>
<td>7.2 (45/624)</td>
<td>17.8 (126/679)</td>
<td>19.5 (136/698)</td>
</tr>
<tr>
<td>Men</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SCORE chart for combined risk among remaining individuals with extrapolation:†</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Unclassifiable‡</td>
<td>Women</td>
<td>7.0 (46)</td>
<td>6.4 (40)</td>
<td>19.7 (76)</td>
<td>6.6 (46)</td>
</tr>
<tr>
<td>Men</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>High risk</td>
<td>Women</td>
<td>18.7 (123)</td>
<td>78.7 (491)</td>
<td>21.7 (154)</td>
<td>68.2 (483)</td>
</tr>
<tr>
<td>Men</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Intermediate risk</td>
<td>Women</td>
<td>61.9 (407)</td>
<td>77.7 (488)</td>
<td>48.5 (330)</td>
<td>4.7 (33)</td>
</tr>
<tr>
<td>Men</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Low risk</td>
<td>Women</td>
<td>8.5 (56)</td>
<td>0 (0)</td>
<td>3.2 (23)</td>
<td>0 (0)</td>
</tr>
<tr>
<td>Men</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total sum of high risk group, according to priority list and SCORE chart</td>
<td>Women</td>
<td>22.5 (148/667)</td>
<td>85.9 (530/664)</td>
<td>39.5 (280/699)</td>
<td>88.7 (619/688)</td>
</tr>
<tr>
<td>Men</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
We have no specific patients with diabetes type 1 and people receiving antihypertensive treatment, irrespective of blood pressure levels. However, all were included, as were patients receiving treatment for hypertension, irrespective of blood pressure levels. Patients with diabetes type 1 without microalbuminuria, conservative estimate of the group before evaluation using the systematic coronary risk evaluation project. 

Higher in the Nord-Trøndelag population than in most comparable countries, but lower than in Finland. The adjustments we made to adapt the data from the Nord-Trøndelag health study to the priority list of the European guidelines, should not significantly affect our main results. People with self reported angina, peripheral artery disease, and high levels of low density lipoprotein cholesterol were not automatically assigned to the high risk group. This contributes to a conservative estimate of the group before evaluation using the chart. Patients with diabetes type 1 without microalbuminuria, however, were included, as were patients receiving treatment for hypertension, irrespective of blood pressure levels. However, all patients with diabetes type 1 and people receiving antihypertensive treatment require a level of attention similar to that of people recently diagnosed as at high risk. We have no specific information on the use of lipid lowering drugs among the participants of the Nord-Trøndelag health study. To the extent that our population may have included patients receiving such treatment, this would contribute to a conservative estimate of the high risk population.

**Applicability of 2003 European guidelines**

Our findings can be discussed with regard to three explicit objectives of the guidelines—that is, the development of a risk estimation system intended for adaptation at national or even local level; a tool for prioritising patients; and an aid to individual risk communication and counselling.

**Adaptation at national level**

A paramount aim of the systematic coronary risk evaluation project was to encourage development of national guidelines on prevention of cardiovascular disease. Applying the Framingham risk equation to European countries overestimated the risk of cardiovascular disease. This highlights the importance of evaluating risk scoring systems against epidemiological data from the population to be screened before implementation in clinical practice. In addition, a country can show regional differences in morbidity and mortality. A dichotomisation of Europe into high risk and low risk regions may maintain the earlier introduced imprecision of the risk assessment. Whether the high risk chart applies to Norway has yet to be investigated.

**Tool for prioritising patients**

The 2003 European guidelines seem to be intended as a tool to define the priorities to be set, given limited resources. We found that the guidelines are unlikely to serve as an effective tool for prioritising Norwegians, as they classify an unreasonable number of people as at high risk. Extrapolation of risk to 60 years contributes strongly to this and implies that no men aged 40 or older and only a few women can be considered as at low risk for cardiovascular disease. Absence of extrapolation, however, makes it theoretically impossible for someone aged 40 to be classified as at high risk on the basis of the systematic coronary risk evaluation chart. So whereas extrapolation of risk leads to an overwhelmingly large high risk group, lack of extrapolation may lead to down prioritising of younger people who might benefit from early intervention.

**Tool for counselling in clinical practice**

The vision of the Third Joint Task Force was to make the guidelines (or adapted ones) part of standard daily clinical practice throughout Europe. The European Society of Cardiology encourages visitors to its website (www.escardio.org) to include these guidelines in their handheld digital systems. The guidelines are therefore clearly recommended for direct use in counselling in clinical practice. Several ethical dilemmas may be linked to implementation of the guidelines in clinical practice. These arise from the likelihood of overestimating someone’s true risk for cardiovascular disease. People who contributed data to the systematic coronary risk evaluation project were mostly recruited in the 1970s and 80s (Norway, 1974-8). Since the beginning of the 1970s, mortality from cardiovascular disease has decreased by 30%-50% in western Europe. Lifestyle and body composition in the Norwegian population has also undergone important changes. A given combination of the relevant risk factors for cardiovascular disease is likely to predict a lower mortality risk today than 25 years ago. The systematic coronary risk evaluation project does not discuss the problem of retrospective risk bias. A Norwegian group on cardiovascular disease has
suggested that a 5% risk for mortality in 1985 may correspond to a 2.5% risk in 2003.13 We question whether it was scientifically justifiable to include the risk charts of the systematic coronary risk evaluation project14 in guidelines intended for implementation in a clinical setting15 before validation in a contemporary context.

Any overestimation of a person’s risk for cardiovascular disease can have important implications. Apart from causing unnecessary concern, it undermines the patient’s informed choice for intervention. It is also likely to increase prescribing costs and affect life insurance premiums.16 As yet little scientific knowledge is available on how the communication of this kind of risk affects people’s understanding of themselves, their bodies, and their lives.17 18

Process for development of guidelines

When guidelines class most adults in one of the world’s longest living and healthiest populations19 as at high risk and therefore in need of maximal clinical attention and follow-up, it raises several scientific and ethical questions.20 The finding predicts major dilemmas related to workload and resource allocation,21 even in Norway where the political, economic, social, and medical circumstances reflect excellent access to health care by international comparison,22 and the per capita expenditure on health is among the highest in the world.23 It may be time to reconsider the aims and means of prevention of cardiovascular disease and the process of developing guidelines.24

Methods for the development of guidelines for prevention of disease should be scientifically consistent so as to ensure that concordance with guidelines is practically feasible and likely to result in the desired outcomes.25 Evidence from biomedical research has limited meaning in isolation; it must be regarded in the context of preventive medicine, both nationally and internationally.26-28 Despite the contribution of numerous experts and professional societies, it seems that authoritative clinical guidelines on the basis of the systematic coronary risk evaluation project may be an example of premature application of medical technology in routine clinical practice.

We thank Kristjana Stella Blöndal (Social Science Research Institute, University of Iceland) for help with data analysis and Ásta Gudjónsdóttir for secretarial assistance.

Contributors: IH conceived the study. JAS, LG, and SR carried out the analyses. LG, IH, and ALK wrote the article with assistance from the other authors. IH, JAS, and JH are guarantors.

Funding: Norwegian University of Science and Technology bioethics research group and the Icelandic Family Physicians Research Fund. Data collection in HUNT 2 was a financial collaboration between the HUNT research centre at the Faculty of Medicine, Norwegian University of Science and Technology, the Norwegian Institute of Public Health, the Nord-Trøndelag County Council, and Levanger hospital. Competing interests: None declared.

Ethical approval: Surveys in the Nord-Tröndelag health study were approved by the Norwegian data inspectorate and the regional committee for ethics in medical research.


Office of Human Resources, Landsdæptun University Hospital, IS-101 Reykjavik.
Iceland
Linn Getz occupational physician
Department of Public Health and General Practice, Norwegian University of Science and Technology, N-7489 Trondheim, Norway
Irene Hedlevik associate professor in general practice
Linn Getz PhD student
Department of Family Medicine, University of Iceland, Neshagi 16, IS-107 Reykjavik, Iceland

Johann A Sigurdsson professor
Anna Luise Kirkengen post doctoral researcher
HUNT Research Centre, Department of Public Health and General Practice, Faculty of Medicine, Norwegian University of Science and Technology, N-7650 Verdal, Norway
Solfrid Romundstad post doctoral researcher
Jostein Holmen professor in community medicine
Correspondence to: L Getz linngetz@med.is